$3.53 Million in Sales Expected for Novavax, Inc. (NASDAQ:NVAX) This Quarter

Analysts expect that Novavax, Inc. (NASDAQ:NVAX) will announce sales of $3.53 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Novavax’s earnings, with the lowest sales estimate coming in at $1.20 million and the highest estimate coming in at $5.40 million. Novavax reported sales of $10.77 million during the same quarter last year, which indicates a negative year-over-year growth rate of 67.2%. The business is expected to report its next quarterly earnings report on Wednesday, August 14th.

On average, analysts expect that Novavax will report full year sales of $11.50 million for the current financial year, with estimates ranging from $5.90 million to $16.00 million. For the next year, analysts expect that the business will report sales of $12.00 million. Zacks’ sales calculations are an average based on a survey of research firms that that provide coverage for Novavax.

Novavax (NASDAQ:NVAX) last issued its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($2.20) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($2.40) by $0.20. The firm had revenue of $3.98 million during the quarter, compared to analysts’ expectations of $4.80 million. During the same period in the previous year, the firm earned ($2.80) EPS.

NVAX has been the topic of several analyst reports. BidaskClub raised shares of Novavax from a “sell” rating to a “hold” rating in a report on Thursday, March 21st. Oppenheimer boosted their price objective on shares of Novavax from $1.25 to $25.00 in a research report on Monday, May 13th. Zacks Investment Research raised shares of Novavax from a “hold” rating to a “buy” rating and set a $15.00 price objective for the company in a research report on Friday, March 22nd. HC Wainwright reissued a “buy” rating and issued a $40.00 price objective on shares of Novavax in a research report on Friday, May 3rd. Finally, Cantor Fitzgerald reissued a “hold” rating on shares of Novavax in a research report on Thursday, May 9th. Two analysts have rated the stock with a sell rating, three have given a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and an average target price of $40.00.

A number of institutional investors have recently added to or reduced their stakes in NVAX. Edmond DE Rothschild Holding S.A. lifted its stake in Novavax by 86.7% during the first quarter. Edmond DE Rothschild Holding S.A. now owns 1,537,130 shares of the biopharmaceutical company’s stock valued at $847,000 after buying an additional 713,752 shares in the last quarter. DekaBank Deutsche Girozentrale lifted its stake in Novavax by 21.8% during the first quarter. DekaBank Deutsche Girozentrale now owns 123,100 shares of the biopharmaceutical company’s stock valued at $185,000 after buying an additional 22,000 shares in the last quarter. SG Americas Securities LLC lifted its stake in Novavax by 3,799.2% during the first quarter. SG Americas Securities LLC now owns 435,107 shares of the biopharmaceutical company’s stock valued at $240,000 after buying an additional 423,948 shares in the last quarter. BNP Paribas Arbitrage SA lifted its stake in Novavax by 7,685.2% during the first quarter. BNP Paribas Arbitrage SA now owns 79,331 shares of the biopharmaceutical company’s stock valued at $44,000 after buying an additional 78,312 shares in the last quarter. Finally, Creative Planning lifted its stake in Novavax by 161.7% during the first quarter. Creative Planning now owns 513,324 shares of the biopharmaceutical company’s stock valued at $283,000 after buying an additional 317,204 shares in the last quarter.

Shares of NASDAQ:NVAX opened at $5.62 on Wednesday. The stock has a market capitalization of $126.97 million, a P/E ratio of -0.56 and a beta of 2.32. The company has a 50-day moving average price of $5.51. Novavax has a fifty-two week low of $4.64 and a fifty-two week high of $51.60.

Novavax Company Profile

Novavax, Inc, together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant that is in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase II clinical trial for treating seasonal influenza in older adults.

See Also: What is a capital gains distribution?

Get a free copy of the Zacks research report on Novavax (NVAX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Novavax (NASDAQ:NVAX)

Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.